Vendor Intelligence Report: Amplified Amino

Published 3 Jul 2026. 21-page investigative report on who is behind Amplified Amino: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Amplified Amino is a short-lived peptide storefront with a mixed lab record and an important timeline correction. Across 12 Finnrick lab tests, the vendor recorded 8 passes and 4 failures, for an overall pass rate of 67%. The pattern is not uniform: semaglutide is the clearest historical positive, BPC-157 is the weak point and aligns with community complaints, while retatrutide is mixed despite a comparatively higher rating and heavier regulatory baggage.

The public record also changes the shutdown story. Archive captures show a functional Shopify store with catalog content and promotions into late 2025, while the canonical domain later failed DNS checks in 2026. That leaves any current offer under the Amplified Amino or Enhanced Amino name needing proof of domain control, entity continuity, and vial-level batch documentation before it can be treated as authentic.

Ownership is partly documented but not resolved. The file ties the brand to AMPLIFIED AMINO LLC and a Texas tax-account record, but the address stack runs through registered-agent and virtual-office locations, with no named operators or confirmed handling site. The strongest network clue is not a social-media rumor; it is an account-layer Shopify artifact linking Amplified Amino with Enhanced Amino, while Profound Aminos remains only a watched successor lead.

Regulatory risk is contextual rather than direct: no public FDA action naming Amplified Amino was found, but peer warning letters target similar peptide, GLP-1, retatrutide, and bacteriostatic-water product mixes. For buyers, the practical read is product-specific and authenticity-specific, not a blanket safe-or-unsafe label.

Inside the full report:

  • Per-product Finnrick interpretation, methodology-divergence charts, spark-grid trajectories, and Appendix A lab data for all three tested products
  • Wayback timeline and DNS evidence showing the storefront active after the mid-2025 closure narrative, then offline later
  • Texas tax-account record, registered-agent and virtual-office address analysis, and unresolved operator-identity leads
  • Shopify backend identifiers and the account-layer artifact connecting Amplified Amino to Enhanced Amino
  • Profound Aminos successor-check evidence, including the email-domain lead and countervailing infrastructure differences
  • FDA peer-enforcement context, archived catalog review, and Reddit BPC-157 complaint captures

Risk assessment

  • Product-quality and batch-traceability risk for BPC-157 and retatrutide — high: BPC-157 recorded 4 tests with 2 pass / 2 fail and a 49.31% rating; retatrutide recorded 4 tests with 2 pass / 2 fail and a 75.93% rating; tested samples lacked batch IDs.
  • Regulatory and shutdown risk — high: Archived catalog included retatrutide, tirzepatide, and bacteriostatic water; no FDA letter to Amplified Amino was found, but 2026 peer warning letters targeted similar product mixes and the official domain is offline.
  • Ownership and operating-location opacity risk — medium: AMPLIFIED AMINO LLC tax-record evidence exists, but no named operators or current formation records were verified; known addresses are virtual-office or registered-agent locations.
  • Brand-confusion and authenticity-verification risk — medium: Enhanced Amino shared account/backend artifacts and is now blank; Profound Aminos remains inconclusive; no official-channel, authorized-reseller, signed-COA, or anti-counterfeit framework was found.